“…Second, previous studies have indicated that neonatal screening for T. gondii IgM using DBS detects ~52-87% of infected newborns (Lebech et al, 1999;Paul et al, 2000;Gilbert et al, 2007). Similarly, the sensitivity of CMV DBS DNA testing approaches 100% when testing symptomatic newborns (Barbi et al, 1996;Snijdewind et al, 2012), but ranges from ~30 to 80% when testing unselected population-based newborns (Soetens et al, 2008;Boppana et al, 2010). While this suggests some case-and control-infants with T. gondii or CMV infection might have been missed with an approach that used residual DBS, the study was most likely to miss those with CMV infection who had a low viral load and thus were at low risk for clinical sequelae related to the infection.…”